Skip to main content
. 2023 Jul 6;13:1200815. doi: 10.3389/fonc.2023.1200815

Figure 3.

Figure 3

Overall survival of patients with glioblastomas using the current classification scheme and its clinical relevance. (A): Kaplan–Meier curves showing the overall survival (OS) of molecular glioblastomas vs. histological glioblastomas (median OS: 11.4 months vs. 15.6 months, hazard ratio [HR]: 0.76, P=0.17), and the OS curve for all glioblastomas (median OS: 12.6 months). In all glioblastomas (B-I), age ≥60 years, males, postoperative treatment without Stupp protocol, MGMT promotor unmethylation, alteration of CIC, KMT5B, CDK4, FGFR3 were correlated with a shorter OS. In histological glioblastomas (J-U), age ≥60 years, postoperative treatment without standardized Stupp protocol, having chromosome 7 gain and chromosome 10 loss, alteration of CDK6, TOP3A, PTEN, MYBL1, KRAS, MYB, FGFR2, CIC, MGMT, promotor unmethylation were correlated with a shorter OS. In molecular glioblastomas (V–AA), male sex, ki-67≥30%, alteration of TP53, CDK4, FGFR3, and KMT5B were correlated with a shorter OS.